Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease

Hye, Abdul; Kerr, Fiona; Archer, Nicola; Foy, Catherine; Poppe, Michaela; Brown, Richard; Hamilton, Gillian; Powell, John; Anderton, Brian; Lovestone, Simon

Abstract

Alzheimer's disease (AD) is a disorder without a molecular marker in peripheral tissues or a disease modifying treatment. As increasing evidence has suggested a role for glycogen synthase kinase-3 (GSK-3) in the pathogenesis of the condition we measured total GSK-3 protein (alpha and beta isoforms) and GSK-3 activity (serine 9 phosphorylation) in a group of healthy elderly people, in AD and in mild cognitive impairment (MCI). Total GSK-3 protein was increased in both AD and in MCI without a compensatory decrease in activity. These data suggest that GSK-3 assays might be a useful diagnostic marker in a readily available tissue and moreover that GSK-3 activity is increased in the prodromal phase of the disorder suggesting that inhibition of GSK-3 might be a useful therapeutic strategy.

Citation

Hye, A., Kerr, F., Archer, N., Foy, C., Poppe, M., Brown, R., …Lovestone, S. (2004). Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease. Neuroscience Letters, 373(1), 1-4. https://doi.org/10.1016/j.neulet.2004.10.031

• Journal Article Type: Article
• Acceptance Date: Oct 13, 2004
• Online Publication Date: Nov 11, 2004
• Publication Date: Dec 13, 2004
• Deposit Date: Oct 27, 2016
• Journal: Neuroscience Letters
• Print ISSN: 0304-3940
• Publisher: Elsevier
• Peer Reviewed: Peer Reviewed
• Volume: 373
• Issue: 1
• Pages: 1-4
• DOI: https://doi.org/10.1016/j.neulet.2004.10.031
• Keywords: Alzheimer's disease; Glycogen synthase kinase-3 (GSK-3); Biomarker; Lymphocytes; White cells; Mild cognitive impairment (MCI)
• Public URL: http://researchrepository.napier.ac.uk/Output/409203